Denali Therapeutics Inc’s recently made public that its Director SATO VICKI L unloaded Company’s shares for reported $34133.0 on May 15 ’24. In the deal valued at $20.39 per share,1,674 shares were sold. As a result of this transaction, SATO VICKI L now holds 116,369 shares worth roughly $2.34 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, SATO VICKI L sold 1,666 shares, generating $30,471 in total proceeds. Upon selling the shares at $18.29, the Director now owns 118,043 shares.
Before that, Krognes Steve E. sold 92,500 shares. Denali Therapeutics Inc shares valued at $1,896,250 were divested by the Director at a price of $20.50 per share. As a result of the transaction, Krognes Steve E. now holds 47,341 shares, worth roughly $0.95 million.
Citigroup initiated its Denali Therapeutics Inc [DNLI] rating to a Buy in a research note published on December 13, 2023; the price target was $32. B. Riley Securities started covering the stock on September 06, 2023. It rated DNLI as “a Buy”.
Price Performance Review of DNLI
On Monday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -1.85% to $20.13. Over the last five days, the stock has gained 4.30%. Denali Therapeutics Inc shares have fallen nearly -6.20% since the year began. Nevertheless, the stocks have fallen -33.67% over the past one year. While a 52-week high of $33.31 was reached on 02/27/24, a 52-week low of $14.56 was recorded on 04/25/24. SMA at 50 days reached $18.67, while 200 days put it at $19.88. A total of 0.86 million shares were traded, compared to the trading of 0.75 million shares in the previous session.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 19.83, which if violated will result in even more drops to 19.54. On the upside, there is a resistance level at 20.57. A further resistance level may holdings at 21.02. The Relative Strength Index (RSI) on the 14-day chart is 61.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.67, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 14.16%. Stochastics %K at 89.02% indicates the stock is a selling.
The most recent change occurred on January 30, 2023 when SVB Securities began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
